About us

Our mission is to develop innovative RNA-based therapeutics that specifically target viruses.

Who are we


Hybridize Pharma is a pre-clinical stage biotech company that spun out from the Leiden University Medical Center in September 2019. We are a R&D-performing SME, creating value by developing RNA-based therapeutics specifically targeting viruses that become reactivated under immunosuppression. Hybridize Pharma has the ambition to become a global player in developing anti-viral therapies.

The concept of Hybridize Pharma was founded in July 2018 by Eric van der Veer, Anton Jan van Zonneveld and Jurriën Prins.

Antisense oligonucleotide picture of the kidney

Our Team


Eric van der Veer Ph.D.

(Scientific) Founder & CEO

Read Bio

Alexander Mentink

Business Development

Read Bio

Scientific co-founders

Prof. Anton Jan van Zonneveld

LUMC

Read Bio

Jurriën Prins

LUMC

Read Bio

Advisors

Dr. Andre Hoekema

CBO Galapagos

Read Bio

Dr. Peter Sijmons

Director at Szienz

Read Bio

Mr. Rogier van der Heijden

Director at Calcasa B.V.

Read Bio

Scientific Advisory Board

Prof. Volker Nickeleit

University of North Carolina

Read Bio

Dr. Mariet Feltkamp

Associate Professor, LUMC

Read Bio

Prof. Annemieke Aartsma-Rus

Professor Human Genetics, LUMC

Read Bio

Network and industry exptertise of Hybridize Pharma


We leverage our extensive network of partners, that are leaders in their respective fields.

Patient associations

Health Care Collaborations

Regulatory Support

Investors

Our large clinical network and access to key opinion leaders includes different Nephrology research expert centers worldwide, among which the University of North Carolina at Chapel Hill School of Medicine, University of California in Los Angeles (UCLA), Hannover Medical Center in Germany and the Erasmus Medical Center (Rotterdam) and University of Groningen Medical Center (UMCG) in the Netherlands.